Pfizer Inc. (NYSE PFE) has been reiterated by The Street Ratings as a buy with a ratings score of A. The company’s strengths can be seen in multiple areas, such as its largely solid financial position with reasonable debt levels by most measures, reasonable valuation levels, increase in stock price during the past year, good cash flow from operations and expanding profit margins. Pfizer Inc. (NYSE:PFE) stock opened at $31.25 in last session, and closed at $31.09, while the day range of company stock is $30.95 – $31.29. The stock showed a negative weekly performance of -0.26%.
Merck & Co., Inc. (NYSE:MRK): MKM Partners upgraded MRK from Neutral to Buy (Nov 20, 2012). Previously, MP Advisors upgraded MRK from Market Perform to Outperform. Merck & Co., Inc. (NYSE:MRK) stock opened at $52.62, in last session and closed at $ 51.95, by losing – 1.05%. The 52 week range of $40.83 – 53.44. Company’s market capitalization is $152.04billion.
Bristol-Myers Squibb Co (NYSE:BMY) In November 2013, Bristol-Myers cut R&D staff, severing nearly all discovery work in diabetes, hepatitis C, and neuroscience. The cuts to the crowded and/or risky indications will largely benefit the company’s immuno-oncology operations. Bristol-Myers Squibb Co (NYSE:BMY) start the session at $52.62 and finished the last session at $51.95. Company’s market capitalization is $152.04 billion.
Arena Pharmaceuticals (NASDAQ:ARNA) CEO Jack Lief sold 100,000 shares of Arena Pharmaceuticals stock on the open market in a transaction dated Friday, January 17th. The stock was sold at an average price of $7.81, for a total transaction of $781,000.00. Following the sale, the chief executive officer now directly owns 583,704 shares of the company’s stock, valued at approximately $4,558,728. Arena Pharmaceuticals (NASDAQ:ARNA )stock opened the session at $7.84, and closed the session at $7.26. The 52 week range of the ARNA stock remained $4.05 – $10.30 and the day range was $7.11 – $7.97.
Leave a Reply